ATE343597T1 - Diagnostisches assay für typ-2-heparin induzierte thrombocytopenie - Google Patents

Diagnostisches assay für typ-2-heparin induzierte thrombocytopenie

Info

Publication number
ATE343597T1
ATE343597T1 AT00961409T AT00961409T ATE343597T1 AT E343597 T1 ATE343597 T1 AT E343597T1 AT 00961409 T AT00961409 T AT 00961409T AT 00961409 T AT00961409 T AT 00961409T AT E343597 T1 ATE343597 T1 AT E343597T1
Authority
AT
Austria
Prior art keywords
type
induced thrombocytopenia
diagnostic assay
heparin induced
heparin
Prior art date
Application number
AT00961409T
Other languages
English (en)
Inventor
Abdelouahed Mustapha
W Lawler John
Original Assignee
Wesagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wesagen Inc filed Critical Wesagen Inc
Application granted granted Critical
Publication of ATE343597T1 publication Critical patent/ATE343597T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, e.g. Konjac gum, Locust bean gum, Guar gum
    • G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/222—Platelet disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
AT00961409T 1999-08-30 2000-08-29 Diagnostisches assay für typ-2-heparin induzierte thrombocytopenie ATE343597T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15131499P 1999-08-30 1999-08-30

Publications (1)

Publication Number Publication Date
ATE343597T1 true ATE343597T1 (de) 2006-11-15

Family

ID=22538197

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00961409T ATE343597T1 (de) 1999-08-30 2000-08-29 Diagnostisches assay für typ-2-heparin induzierte thrombocytopenie

Country Status (7)

Country Link
US (1) US7011953B2 (de)
EP (1) EP1254181B1 (de)
AT (1) ATE343597T1 (de)
AU (1) AU7336400A (de)
CA (1) CA2401411A1 (de)
DE (1) DE60031576D1 (de)
WO (1) WO2001016184A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7732213B2 (en) * 1999-02-22 2010-06-08 Coramed Healthcare, Inc. Method of evaluating patient hemostasis
US7179652B2 (en) * 1999-02-22 2007-02-20 Haemoscope Corporation Protocol for monitoring platelet inhibition
US8008086B2 (en) * 1999-02-22 2011-08-30 Cora Healthcare, Inc. Protocol for monitoring direct thrombin inhibition
US7655411B2 (en) * 2002-08-23 2010-02-02 W2 Holdings, Inc. Thrombospondin fragments and binding agents in the detection, diagnosis and evaluation of cancer
US7524670B2 (en) * 2003-08-05 2009-04-28 Haemoscope Corporation Protocol and apparatus for determining heparin-induced thrombocytopenia
US20060074049A1 (en) * 2004-10-05 2006-04-06 Mitchell Krathwohl Use of heparinoids for treatment and prevention of dementia
FR2902884B1 (fr) * 2006-06-23 2008-12-26 Hyphen Biomed Soc Par Actions Procede pour la detection des anticorps heparine-dependants et le diagnostic des pathologies immunes ou auto-immnues potentialisees par l'heparine telle que la thrombopenie induite par l'heparine
US8940495B2 (en) 2008-02-29 2015-01-27 BioMedomics, Inc Rapid and sensitive method for quantitative determination of the level of heparin—PF4 complex induced immunoglobulin antibodies
ES2561984T3 (es) * 2008-08-27 2016-03-01 Lsi Medience Corporation Anticuerpo anticomplejo heparina/FP4 modificado y patrón de anticuerpo TIH
WO2013042111A2 (en) * 2011-01-20 2013-03-28 Aaron Tomer Platelet analysis system
US9599623B2 (en) 2011-06-09 2017-03-21 Immucor Gti Diagnostics, Inc. Diagnostic devices, methods and systems for detecting platelet factor 4 (PF4)/heparin antibodies
EP2828658B1 (de) * 2012-03-23 2017-06-14 The Trustees Of The University Of Pennsylvania Verfahren zur identifikation von hit-antikörpern und pf4-antikörpern sowie zelllinien zur verwendung darin
WO2013165969A2 (en) * 2012-05-01 2013-11-07 The Trustees Of The University Of Pennsylvania Methods and kits for diagnosing heparin-induced thrombocytopenia
ES2924187T3 (es) * 2017-03-29 2022-10-05 Emosis Un ensayo funcional de trombocitopenia inducida por heparina, rápido y bajo demanda
CN108956998A (zh) * 2018-04-11 2018-12-07 中翰盛泰生物技术股份有限公司 一种应用免疫荧光干式定量法的肝素结合蛋白测定试剂盒及测定方法
CN112255416A (zh) * 2020-09-29 2021-01-22 北京利德曼生化股份有限公司 使用磁微粒化学发光定量检测hbp的试剂盒及其制备、检测方法
CN115490766A (zh) * 2022-09-16 2022-12-20 山东大学 一种人pf4的特征多肽及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281061A (en) * 1979-07-27 1981-07-28 Syva Company Double antibody for enhanced sensitivity in immunoassay
US4444879A (en) * 1981-01-29 1984-04-24 Science Research Center, Inc. Immunoassay with article having support film and immunological counterpart of analyte
US5466582A (en) * 1990-08-09 1995-11-14 Serbio Thrombocytopenia determination
US5585243A (en) 1993-09-15 1996-12-17 The Blood Center Of Southeastern Wisconsin, Inc. Method of detecting cytopenia that is mediated by drug-dependent antibody binding to blood cells
US5763201A (en) * 1996-02-05 1998-06-09 Emory University Flow cytometry assay for heparin-induced thrombocytopenia
US5972718A (en) * 1996-02-28 1999-10-26 The Blood Center Research Foundation Method of detecting heparin-induced thrombocytopenia
WO2000002587A1 (en) * 1998-07-13 2000-01-20 Board Of Regents, The University Of Texas System Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids

Also Published As

Publication number Publication date
WO2001016184A3 (en) 2001-06-21
AU7336400A (en) 2001-03-26
EP1254181A2 (de) 2002-11-06
WO2001016184A2 (en) 2001-03-08
DE60031576D1 (en) 2006-12-07
US20020197697A1 (en) 2002-12-26
EP1254181B1 (de) 2006-10-25
US7011953B2 (en) 2006-03-14
CA2401411A1 (en) 2001-03-08

Similar Documents

Publication Publication Date Title
ATE343597T1 (de) Diagnostisches assay für typ-2-heparin induzierte thrombocytopenie
ATE361935T1 (de) Monoklonale antikörper spezifisch für die extrazelluläre domäne des prostata-spezifischen membranantigens
ATE351921T1 (de) Verfahren für fluoreszenzerkennungstest
ATE318147T1 (de) Spezifische monoklonale antikörperfür die extrazelluläre domäne von protasta-spezifischem membranantigen
DE59903915D1 (de) Verfahren zur frühen diagnose von carcinomen
DE69638050D1 (de) Hemopoietin-rezeptor und dafür kodierende genetische sequenzen
DK0749325T3 (da) Bispecifikke molekyler med klinisk anvendelse
TR200000113T2 (tr) Tüberkülozu teşhis etmek için bileşikler ve bunları kullanma yöntemleri.
ATE212130T1 (de) Chemilumineszenz-immunoassay für den antikörpernachweis
DE69111544D1 (de) Sonde für die photoakustische Analyse.
DE69630808D1 (de) Factor v verhältnis bluttest auf empfänglichkeit für thromboembolie
DE69028095D1 (de) M-csf-monoklonale antikörper, die ein neutralisierendes konformationales epitop erkennen
ES2164822T3 (es) Biosensores sensibles a la masa.
ATE275268T1 (de) Verfahren zur diagnose von sjögren-syndrom
ATE277352T1 (de) Einetenascin-c isoform als marker für neoplasmen
ATE420365T1 (de) Präparierung von sphären für diagnostische tests
ATE223055T1 (de) Verfahren zur diagnose von chlamydia in einer biologischen extrazellulären flüssigkeit
KR870002453A (ko) 프로좀 단백질에 대한 단일항체의 제조방법 및 그를 이용한 프로좀과 관련된 현상의 검출 및 질병의 진단법
EA199800959A1 (ru) ПРИМЕНЕНИЕ ГЕНЕТИЧЕСКОЙ МОДИФИКАЦИИ В ГЕНЕ b3- СУБЪЕДИНИЦЫ ЧЕЛОВЕЧЕСКОГО G-ПРОТЕИНА ДЛЯ ДИАГНОСТИКИ ЗАБОЛЕВАНИЙ
PT1190245E (pt) Deteccao de alergenos
SE9602234D0 (sv) A novel diagnostic method utilizing ECP, and reagents to be used in the methods
DE3852498D1 (de) Enzymtest für biologische substanzen.
ATE302416T1 (de) Auf holo-transcobalamin ii beruhendes diagnostisches verfahren für alzheimer-krankheit
ATE118032T1 (de) Monoklonale antikörper und diagnoseverfahren für phytophthora-infektionen.
DE59813830D1 (de) Nukleinsäuremolekülsatz für salmonella-nachweis, nukleinsäuren, kit und verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties